Key facts
- This page summarizes Christopher R. Loose's Form 4 filing for Frequency Therapeutics, Inc. (KRRO).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 31 Jul 2023, 16:01.
Christopher R. Loose - 27 Jul 2023 Form 4 Insider Report for Frequency Therapeutics, Inc. (KRRO)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- KRRO
- Reported as of
- 27 Jul 2023
- Net transaction value
- -$1,346
- SEC form
- 4
- Accepted by SEC
- 31 Jul 2023, 16:01:34 UTC
- Prior SEC filing
- 27 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ James P. Abely, Attorney-in-Fact for Christopher R. Loose
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher R. Loose filed Form 4 for Frequency Therapeutics, Inc. (KRRO) on 31 Jul 2023.
Change
- Previous filing in this sequence was filed on 27 Jul 2023.
- Current net transaction value: -$1,346.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FREQ
transaction
Common Stock
Sale
- Transaction value
- $728
- Shares
- -1,373
- Change %
- -0.74%
- Price
- $0.5300
- Shares after
- 184,994
- Date
- 27 Jul 2023
- Ownership
- Direct
- Footnotes
- F1, F2
FREQ
transaction
Common Stock
Sale
- Transaction value
- $618
- Shares
- -1,344
- Change %
- -0.73%
- Price
- $0.4600
- Shares after
- 183,650
- Date
- 28 Jul 2023
- Ownership
- Direct
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person.
Footnote F2
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.502 to $0.543. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
Footnote F3
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.461 to $0.471. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.